NRF launches cybersecurity and synthetic biology consortiums to help companies tap new technologies

NRF launches cybersecurity and synthetic biology consortiums to help companies tap new technologies

Trinity Chua
20/09/16, 07:26 pm

SINGAPORE (Sept 20): Two new consortiums in cybersecurity and synthetic biology were launched today to spur collaborations between industry players, government agencies and research institutions.

The Singapore Cybersecurity Consortium (SGCC) and the Singapore Consortium for Synthetic Biology (SINERGY) are supported by the National Research Foundation. They will be hosted at the National University of Singapore.

“The idea of a consortium is to [bring together] our researchers who have received funding from us [NRF], and have created a portfolio of IPs and know-how through their research. The intent is to bring the industry [the companies that are interested in these technologies] now to them,” says CEO of NRF, Professor Low Teck Seng, at the opening of the Singapore Week of Innovation and TeCHnology (SWITCH).

Low says that most companies around the world are cutting down their R&D budget amid a tougher business environment.

Through the consortiums, companies can leverage on the expertise of the research institutions to bring new technologies to market in a more efficient manner.

Companies that “leverage research from the consortiums for collaborative projects with researchers” can also apply for co-funding from the NRF.

NRF has invested $42 million in seven research projects under the National Cybersecurity R&D Programme and $34 million in eight synthetic biology related R&D projects so far. The consortiums will build on these projects, and seek opportunities to bring them to market.

There are currently 14 industry players in the cybersecurity consortium, including StarHub, ST Electronics, Singapore Telecommunications, PwC Singapore and Standard Chartered Bank Singapore. The synthetic biology consortium has more than 10 companies as members, including GlaxoSmithKline and Wilmar International. Consortium members will have access to a range of activities such as global networking opportunities, grant calls for seed grants, training and workshops.

Already, the institutions and industry players within the consortiums are working together. One instance is NTUitive, the commercialisation arm of Nanyang Technological University, which is incubating AdvanceSyn Studio. The latter is a company that does predictive biological engineering.

“We hope to tap onto the interaction platform that the Consortium provides, to further the international partnerships of our technologies and spinoff companies,” says Lim Jui, CEO of NTU Innovation and NTUitive.

NRF previously launched two consortiums, which led to at least six collaborative projects.

In 2018, reliable income does not come by easy

SINGAPORE (Feb 21): These days, reliable income is hard to come by. Income is a top objective for most investors and it is the main outcome they want to achieve when investing. After the Global Financial Crisis (GFC), relying on “old-school” savings products, such as depositing money in a savings account or purchasing government bonds, as a sole source of income came to an end. See: Could we see a return to living on interest income? Plummeting growth and the drying up of credit forced the hand of central banks. Interest rates were cut to record lows in an attempt to encourage ....

BRC Asia offers 42 cents per share for all Lee Metal shares

SINGAPORE (Feb 21): BRC Asia is making a voluntary conditional cash offer of 42 cents a share for all the issued shares in Lee Metal Group. The offer price represents a 2.4% premium over Lee Metal’s last traded price of 41 cents on Tuesday. It is also a 32.9% premium above the volume weighted average price (VWAP) for the 12-month period prior to Lee Metal’s last undisturbed trading day on Nov 10, 2017, when an announcement was made regarding a notification by certain shareholders of an unsolicited approach in relation to their shares. According to the pre-conditional offer announc....

TalkMed kept at 'neutral' until return of suspended CEO Dr Ang

SINGAPORE (Feb 21): RHB is maintaining its "neutral" call on TalkMed as CEO Dr Ang Peng Tiam is still serving his eight-month suspension, which started on Jul 25 2017 and is expected to be back on March 26 or towards the end of 1Q18. RHB also expects Dr Ang to take some time before ramping up to full utilisation again. "As a result, we are expecting a weaker 1Q18 ahead vs 1Q17. Hence, we maintain our "neutral" rating with an unchanged DCF-derived target price of 72 cents," says analyst Jarick Seet in a Wednesday report. Management has taken steps to minimise the disruption to its pati....